Biomark Diagnostics Inc. (BUX.CN)
- Previous Close
0.2800 - Open
0.0000 - Bid --
- Ask --
- Day's Range
0.0000 - 0.0000 - 52 Week Range
0.0000 - 0.2800 - Volume
0 - Avg. Volume
6,710 - Market Cap (intraday)
25.448M - Beta (5Y Monthly) -0.40
- PE Ratio (TTM)
-- - EPS (TTM)
-0.0200 - Earnings Date --
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
Biomark Diagnostics Inc., an oncology focused company, develops cancer diagnostic platform to detect, monitor, and treat cancer. The company invests in and develops liquid biopsy metabolic panel assay for early stage diagnosis of lung cancer. It has a strategic partnership with Rubix LS to develop diagnostic tools to enhance lung cancer screening and improve breast cancer screening program for women with dense breasts. The company was incorporated in 2014 and is headquartered in Richmond, Canada.
www.biomarkdiagnostics.comRecent News: BUX.CN
View MorePerformance Overview: BUX.CN
Trailing total returns as of 5/9/2025, which may include dividends or other distributions. Benchmark is S&P/TSX Composite index (^GSPTSE) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: BUX.CN
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: BUX.CN
View MoreValuation Measures
Market Cap
25.45M
Enterprise Value
25.91M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
153.95
Price/Book (mrq)
--
Enterprise Value/Revenue
167.10
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-107.55%
Return on Equity (ttm)
--
Revenue (ttm)
155.03k
Net Income Avi to Common (ttm)
-1.9M
Diluted EPS (ttm)
-0.0200
Balance Sheet and Cash Flow
Total Cash (mrq)
88.58k
Total Debt/Equity (mrq)
--
Levered Free Cash Flow (ttm)
-251.1k